Filana Therapeutics (FLNA) vs GridAI Technologies (GRDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GridAI Technologies (GRDX) has outperformed Filana Therapeutics (FLNA) over the past year, gaining 20.6% versus a loss of 77.7%. Over five years, FLNA leads with a -98.9% price change compared with -100.0% for GRDX. GridAI Technologies is the larger company by market cap ($32.4 million vs $32.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLNA | GRDX |
|---|---|---|
| Share price | $0.6413 | $3.16 |
| Market cap | $32.26M | $32.44M |
| 1-day change | +14.52% | -8.41% |
| YTD return | -67.61% | -32.19% |
| 1-year return | -77.66% | +20.61% |
| 5-year return | -98.85% | -99.99% |
| EPS (TTM) | $-0.87 | $-5.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $36.25K |
| Net income (latest FY) | $-90.97M | $-6.39M |
| Gross margin | — | -1813.56% |
| Operating margin | — | -19539.98% |
| Net margin | — | -17634.42% |
| 52-week high | $3.45 | $6.93 |
| 52-week low | $0.39 | $1.87 |
| Distance from 52-week high | -81.41% | -54.39% |
| Analyst consensus | none | — |
| Avg. price target upside | +913.57% | — |
| Average volume | 2.09M | 120.78K |
| Shares outstanding | 50.30M | 10.27M |
| Employees | 17 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRDX has outperformed FLNA by 98.3 percentage points over the past year.
About Filana Therapeutics
FLNA stock →Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About GridAI Technologies
GRDX stock →GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Health Care · Biotechnology: Pharmaceutical Preparations
FLNA vs GRDX FAQ
Which is bigger, Filana Therapeutics or GridAI Technologies?
GridAI Technologies (GRDX) is larger, with a market capitalization of $32.44M compared with $32.26M for Filana Therapeutics (FLNA).
Which stock has performed better over the past year, FLNA or GRDX?
GRDX returned +20.61% over the past 12 months, compared with -77.66% for FLNA (price return, excluding dividends). Past performance does not predict future results.
Are Filana Therapeutics and GridAI Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.